2e,6e-farnesol is a lipid of Prenol Lipids (PR) class. 2e,6e-farnesol is associated with abnormalities such as Granulomatous Disease, Chronic, pathologic fistula and Cavitation. The involved functions are known as Regulation, Metabolic Inhibition, cholesterol biosynthetic process, Process and Transcription, Genetic. 2e,6e-farnesol often locates in Plasma membrane, Cytoplasmic matrix, cornified envelope, Epidermis and peroxisome. The associated genes with 2E,6E-farnesol are RAB3A gene, FOSL1 gene, CASP8AP2 gene, RCC1 gene and GALE gene. The related lipids are Sterols, Membrane Lipids and Steroids.
To understand associated biological information of 2E,6E-farnesol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
2E,6E-farnesol is suspected in Granulomatous Disease, Chronic, pathologic fistula and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with 2E,6E-farnesol
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Costa CB et al. | Farnesyltransferase inhibitors: molecular evidence of therapeutic efficacy in acute lymphoblastic leukemia through cyclin D1 inhibition. | 2012 | Anticancer Res. | pmid:22399601 |
Schlitzer M and Dahse HM | Structure activity relationship of antiproliferative N-acyl-beta-alanine amides. | 2000 Nov-Dec | Anticancer Res. | pmid:11205283 |
Shirtliff ME et al. | Farnesol-induced apoptosis in Candida albicans. | 2009 | Antimicrob. Agents Chemother. | pmid:19364863 |
Chen F et al. | Tooth-binding micelles for dental caries prevention. | 2009 | Antimicrob. Agents Chemother. | pmid:19704121 |
Brilhante RS et al. | Effect of farnesol on growth, ergosterol biosynthesis, and cell permeability in Coccidioides posadasii. | 2013 | Antimicrob. Agents Chemother. | pmid:23459491 |
Langford ML et al. | Activity and toxicity of farnesol towards Candida albicans are dependent on growth conditions. | 2010 | Antimicrob. Agents Chemother. | pmid:19933803 |
Yu LH et al. | Possible inhibitory molecular mechanism of farnesol on the development of fluconazole resistance in Candida albicans biofilm. | 2012 | Antimicrob. Agents Chemother. | pmid:22106223 |
Sharma M and Prasad R | The quorum-sensing molecule farnesol is a modulator of drug efflux mediated by ABC multidrug transporters and synergizes with drugs in Candida albicans. | 2011 | Antimicrob. Agents Chemother. | pmid:21768514 |
Brilhante RS et al. | Sesquiterpene farnesol contributes to increased susceptibility to β-lactams in strains of Burkholderia pseudomallei. | 2012 | Antimicrob. Agents Chemother. | pmid:22290941 |
Kostoulias X et al. | Impact of a Cross-Kingdom Signaling Molecule of Candida albicans on Acinetobacter baumannii Physiology. | 2015 | Antimicrob. Agents Chemother. | pmid:26482299 |
Stoddart CA et al. | Oral administration of the nucleoside EFdA (4'-ethynyl-2-fluoro-2'-deoxyadenosine) provides rapid suppression of HIV viremia in humanized mice and favorable pharmacokinetic properties in mice and the rhesus macaque. | 2015 | Antimicrob. Agents Chemother. | pmid:25941222 |
Rossignol T et al. | Transcriptional response of Candida parapsilosis following exposure to farnesol. | 2007 | Antimicrob. Agents Chemother. | pmid:17684006 |
Hornby JM et al. | Farnesol biosynthesis in Candida albicans: cellular response to sterol inhibition by zaragozic acid B. | 2003 | Antimicrob. Agents Chemother. | pmid:12821501 |
Cao YY et al. | cDNA microarray analysis of differential gene expression in Candida albicans biofilm exposed to farnesol. | 2005 | Antimicrob. Agents Chemother. | pmid:15673737 |
Jabra-Rizk MA et al. | Effect of farnesol on Staphylococcus aureus biofilm formation and antimicrobial susceptibility. | 2006 | Antimicrob. Agents Chemother. | pmid:16569866 |
Brehm-Stecher BF and Johnson EA | Sensitization of Staphylococcus aureus and Escherichia coli to antibiotics by the sesquiterpenoids nerolidol, farnesol, bisabolol, and apritone. | 2003 | Antimicrob. Agents Chemother. | pmid:14506058 |
Falsetta ML et al. | Novel antibiofilm chemotherapy targets exopolysaccharide synthesis and stress tolerance in Streptococcus mutans to modulate virulence expression in vivo. | 2012 | Antimicrob. Agents Chemother. | pmid:22985885 |
Dumitru R et al. | Defined anaerobic growth medium for studying Candida albicans basic biology and resistance to eight antifungal drugs. | 2004 | Antimicrob. Agents Chemother. | pmid:15215080 |
Rodrigues Goulart H et al. | Terpenes arrest parasite development and inhibit biosynthesis of isoprenoids in Plasmodium falciparum. | 2004 | Antimicrob. Agents Chemother. | pmid:15215101 |
Hornby JM and Nickerson KW | Enhanced production of farnesol by Candida albicans treated with four azoles. | 2004 | Antimicrob. Agents Chemother. | pmid:15155241 |